Peer Review reports
From: Migraine, interferon β1a and siponimod immunomodulator therapies
| Original Submission | ||
|---|---|---|
| 22 Jul 2021 | Submitted | Original manuscript |
| 28 Aug 2021 | Author responded | Author comments - Ashraf A. Dahaba |
| Resubmission - Version 2 | ||
| 28 Aug 2021 | Submitted | Manuscript version 2 |
| 29 Oct 2021 | Reviewed | Reviewer Report - Hassan Ali |
| 5 Dec 2021 | Author responded | Author comments - Ashraf A. Dahaba |
| Resubmission - Version 3 | ||
| 5 Dec 2021 | Submitted | Manuscript version 3 |
| 8 Dec 2021 | Reviewed | Reviewer Report - Hassan Ali |
| 1 Feb 2022 | Reviewed | Reviewer Report |
| 28 Feb 2022 | Author responded | Author comments - Ashraf A. Dahaba |
| Resubmission - Version 4 | ||
| 28 Feb 2022 | Submitted | Manuscript version 4 |
| 7 Mar 2022 | Reviewed | Reviewer Report |
| 8 Mar 2022 | Author responded | Author comments - Ashraf A. Dahaba |
| Resubmission - Version 5 | ||
| 8 Mar 2022 | Submitted | Manuscript version 5 |
| 24 Mar 2022 | Author responded | Author comments - Ashraf A. Dahaba |
| Resubmission - Version 6 | ||
| 24 Mar 2022 | Submitted | Manuscript version 6 |
| Publishing | ||
| 29 Mar 2022 | Editorially accepted | |
| 5 Apr 2022 | Article published | 10.1186/s12871-022-01639-z |
You can find further information about peer review here.